Key result
Diffusion-weighted CMR shows substantial agreement with ECV mapping for detecting diffuse myocardial fibrosis in HCM.
Why the study?
Does diffusion-weighted cardiovascular magnetic resonance (DW-CMR) accurately detect diffuse myocardial fibrosis compared to extracellular volume (ECV) CMR in patients with hypertrophic cardiomyopathy?
Cross-Sectional (n=23)
No
Does diffusion-weighted cardiovascular magnetic resonance (DW-CMR) accurately detect diffuse myocardial fibrosis compared to extracellular volume (ECV) CMR in patients with hypertrophic cardiomyopathy?
DW-CMR is a promising contrast-free imaging technique that demonstrates high sensitivity and specificity for detecting diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy, comparable to established ECV CMR.
Answers are grounded in this paper and cite their sources.
May support DW-CMR as contrast-free fibrosis assessment in HCM; hypothesis-generating and requires prospective validation before practice change.
BACKGROUNDS: Previous studies have shown that diffusion-weighted cardiovascular magnetic resonance (DW-CMR) is highly sensitive to replacement fibrosis of chronic myocardial infarction. Despite this sensitivity to myocardial infarction, DW-CMR has not been established as a method to detect diffuse myocardial fibrosis. We propose the application of a recently developed DW-CMR technique to detect diffuse myocardial fibrosis in hypertrophic cardiomyopathy (HCM) patients and compare its performance with established CMR techniques. METHODS: HCM patients (N = 23) were recruited and scanned with the following protocol: standard morphological localizers, DW-CMR, extracellular volume (ECV) CMR, and late gadolinium enhanced (LGE) imaging for reference. Apparent diffusion coefficient (ADC) and ECV maps were segmented into 6 American Heart Association (AHA) segments. Positive regions for myocardial fibrosis were defined as: ADC > 2.0 μm(2)/ms and ECV > 30%. Fibrotic and non-fibrotic mean ADC and ECV values were compared as well as ADC-derived and ECV-derived fibrosis burden. In addition, fibrosis regional detection was compared between ADC and ECV calculating sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) using ECV as the gold-standard reference. RESULTS: ADC (2.4 ± 0.2 μm(2)/ms) of fibrotic regions (ADC > 2.0 μm(2)/ms) was significantly (p < 0.01) higher than ADC (1.5 ± 0.2 μm(2)/ms) of non-fibrotic regions. Similarly, ECV (35 ± 4%) of fibrotic regions (ECV > 30%) was significantly (p < 0.01) higher than ECV (26 ± 2%) of non-fibrotic regions. In fibrotic regions defined by ECV, ADC (2.2 ± 0.3 μm(2)/ms) was again significantly (p < 0.05) higher than ADC (1.6 ± 0.3 μm(2)/ms) of non-fibrotic regions. In fibrotic regions defined by ADC criterion, ECV (34 ± 5%) was significantly (p < 0.01) higher than ECV (28 ± 3%) in non-fibrotic regions. ADC-derived and ECV-derived fibrosis burdens were in substantial agreement (intra-class correlation = 0.83). Regional detection between ADC and ECV of diffuse fibrosis yielded substantial agreement (κ = 0.66) with high sensitivity, specificity, PPV, NPV, and accuracy (0.80, 0.85, 0.81, 0.85, and 0.83, respectively). CONCLUSION: DW-CMR is sensitive to diffuse myocardial fibrosis and is capable of characterizing the extent of fibrosis in HCM patients.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2015) conducted a cross-sectional in Hypertrophic cardiomyopathy (n=23). Diffusion-weighted cardiovascular magnetic resonance (DW-CMR) vs. Extracellular volume (ECV) CMR was evaluated on Regional detection of diffuse myocardial fibrosis (κ = 0.66, p=< 0.001). Diffusion-weighted cardiovascular magnetic resonance demonstrated substantial agreement with extracellular volume mapping for detecting diffuse myocardial fibrosis in hypertrophic cardiomyopathy patients.
Synapse has enriched 10 related papers. Consider them for comparative context: